Inside the HRSA Audit Questions That Make or Break a 340B Software Pitch
A hospital pharmacy team doesn’t go looking for new 340B software because the old one is slow. They go looking because a self-audit turned up a mapping error, an HRSA audit notice just landed, or a new child site is about to go live and nobody’s confident the eligibility logic will hold up under scrutiny. The 340B Drug Pricing Program lets covered entities buy outpatient drugs at steep discounts, but every dollar of that discount comes with a compliance obligation the entity carries alone - and vendors selling split-billing and compliance software into this space are solving a real, audit-driven problem. Most outbound into the niche still reads like generic pharmacy software copy, which is a mismatch with how specific and skeptical this buyer actually is.
What does 340B split-billing software actually need to get right?
It has to separate every drug purchase and dispense into the correct bucket - 340B-eligible, GPO, or wholesale acquisition cost (WAC) - in real time, at the point the prescription is filled, not after the fact in a reconciliation batch. The hard part is mapping National Drug Codes to the hospital’s charge codes correctly and keeping that crosswalk current as both change, since a stale mapping doesn’t throw an error - it just silently bills the wrong account, and that’s exactly the kind of discrepancy an HRSA auditor is trained to find.
Why is this buyer so much more cautious than a typical hospital software evaluation?
Because the downside isn’t a bad user experience - it’s program-wide exposure. HRSA can audit a covered entity at any time, and a pattern of diversion (340B drugs dispensed to ineligible patients) or duplicate discounts (a drug discounted under both 340B and Medicaid rebate) can trigger repayment obligations or put the entity’s entire 340B eligibility at risk. A 340B program manager or pharmacy director evaluating software is really evaluating how much audit liability they’re personally signing off on - a close cousin of the exposure that makes denial-management and compliance software buyers at hospitals equally slow to move on an unproven vendor.
Who’s the actual buyer, and what do they already know?
Usually a 340B program manager, pharmacy director, or a compliance officer at a hospital, health system, or FQHC - someone who already knows the regulatory vocabulary cold. This isn’t a buyer who needs 340B explained to them. Outreach that opens with a basic definition of the program reads as a vendor who hasn’t sold into this space before.
Why do hospitals with multiple sites have it harder?
Eligibility is determined site by site and encounter by encounter - a drug administered in a registered outpatient clinic may qualify while the same drug given inpatient doesn’t. Systems running multiple child sites are managing eligibility logic that changes by location and by claim, which is where general pharmacy systems without 340B-specific configuration fall short.
What should outbound actually lead with?
Automated NDC-to-charge-code crosswalk maintenance, real-time eligibility determination at the point of dispense, and audit-ready reporting that reconstructs a defensible trail for HRSA on demand. Naming split-billing accuracy or duplicate-discount prevention directly signals a vendor built for 340B.
Talk to us if your outbound to hospital 340B teams still reads like general pharmacy software instead of speaking to the split-billing accuracy and HRSA audit exposure this buyer actually loses sleep over.